Maria Sibilia
Scientist & Cancer Researcher, Professor for Tumorbiology, Director of the Center for Cancer Research, Medical University of Vienna & CCC, President of the Senate of the Medical University.
#cancer #signaling #tumorimmunology #innate-immunity
- Reposted by Maria Sibilia@josjonkers.bsky.social @olivierpertz.bsky.social @maria-sibilia.bsky.social @lwellberg.bsky.social Please hit repost and help spread the word - Thank you!
- Don‘t miss it 🔝
- 💰ECR grants for #FGF26 now available to help defray the meeting costs for those in junior faculty. Details on how to apply - click here ➡️https://bit.ly/47ivjOf ⌛️Don't forget talk submission closes soon, submit your abstract now and join us in sunny Malta next May. 🌞 #FusionCellBio
- Join us at our first DDM Summit diring the UEG week in Berlin ! 🎉 Very excited to organize this meeting with M. Heikenwälder and F. Real. This new meeting format is designed for basic and translational scientists interested in GI tract diseases and cancer. 📍 Join us onsite in Room New York!
- Eine große Aufgabe und Verantwortung! Ich freue mich sehr weiterhin als Senatsvorsitzende zusammen mit den Senatsmitglieder die MedUni mitgestalten zu dürfen. Danke für das grosse Vertrauen!
- Der #Senat der #MedUniWien hat mit 1. Oktober die Arbeit aufgenommen. Die Funktionsperiode des Gremiums der #Universität läuft bis Ende September 2028. @maria-sibilia.bsky.social vom Zentrum für #Krebsforschung wurde erneut zur Vorsitzenden gewählt. ⬇️
- Reposted by Maria Sibilia🎤 Meet Our Speaker: Dr. @maria-sibilia.bsky.social , from Center for Cancer Research, Medical University of Vienna (Vienna, Austria) as a speaker at the Targeting RAS Symposium 2025. Dr. Sibilia will giver her talk during Session 10 on Day 3 at 11:15h. 🔗 targetingras.com/registration/
- Our paper is now out with Cover! It reveals the specific role of EGFR in Ras mutant colorectal tumors which include metabolic rewiring, incresed stemness and more….all driven by Smoc2. have a look 👇👇🔝
- Our June issue is online! www.embopress.org/toc/17574684... The beautiful cover highlights the article by @maria-sibilia.bsky.social & al. on the tumor-intrinsic role of #EGFR in #KRAS mutant #ColorectalCancer 👉 doi.org/10.1038/s443... Scientific image: D. Kirchhofer, D. Krauß & M. Sibilia
- Check out our new paper! We identified Smoc2 as an interesting target that is upregulated upon EGFR deletion, driving stemness signatures, reduction in cell size and metabolic rewiring. 💪 🔝👍
- Online today! 👉 #EGFR controls transcriptional & metabolic rewiring in KRASG12D #ColorectalCancer By D. Krauẞ, @maria-sibilia.bsky.social & colleagues at @meduniwien.ac.at 🗞️ doi.org/10.1038/s443...
- I am deeply enthusiastic about contributing to elevate this journal to the highest ranks #science #drugdiscovery #openaccess #biomedicalresearch #cancer #aging #neurology #genomics #precisionmedicine #Elsevier
- Reposted by Maria SibiliaCan metastatic cancer be outsmarted by using the body’s innate immune system? At #CIMT2025, @maria-sibilia.bsky.social will present translational insights from mechanisms to therapeutics—exploring how the innate immune system can be harnessed to fight metastatic disease. www.meeting.cimt.eu
- Vienna: start 13.00 in front of the main University building 🔝 👏👏
- Welcome to the Bluesky account for Stand Up for Science 2025! Keep an eye on this space for updates, event information, and ways to get involved. We can't wait to see everyone #standupforscience2025 on March 7th, both in DC and locations nationwide! #scienceforall #sciencenotsilence
- Thank you for the great organisation ! @fusionconf.bsky.social
- An exciting conference is just about to start 🔝💪👍 @fusionconf.bsky.social
- Reposted by Maria SibiliaOnline now at Nature Cancer! @maria-sibilia.bsky.social and team propose a strategy to boost immunotherapy by combining topically applied TLR7/8 agonists with systemic interferon-I, sensitizing dendritic cells to produce IL-12 for tumor clearance 👇 www.nature.com/articles/s43...
